Martínez-Gopar Pablo E, Pérez-Rodríguez Marian J, Angeles-López Quetzalli D, Tristán-López Luis, González-Espinosa Claudia, Pérez-Severiano Francisca
Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, Unidad Sede Sur, Calzada de los Tenorios No. 235, Colonia Granjas Coapa, Alcaldía Tlalpan, 14330, Mexico City, CP, Mexico.
Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez", Avenida Insurgentes Sur No. 3877, Colonia La Fama, Alcaldía Tlalpan, 14269, Mexico City, CP, Mexico.
Mol Neurobiol. 2023 May;60(5):2678-2690. doi: 10.1007/s12035-023-03234-w. Epub 2023 Jan 26.
Toll-like receptors (TLRs) are central players in innate immunity responses. They are expressed in glial cells and neurons, and their overactivation leads to the production of proinflammatory molecules, neuroinflammation, and neural damage associated with many neurodegenerative pathologies, such as Huntington's disease (HD). HD is an inherited disorder caused by a mutation in the gene coding for the protein Huntingtin (Htt). Expression of mutated Htt (mHtt) causes progressive neuronal degeneration characterized by striatal loss of GABAergic neurons, oxidative damage, neuroinflammatory processes, and impaired motor behavior. The main animal models to study HD are the intrastriatal injection of quinolinic acid (QA) and the transgenic B6CBA-Tg (HDexon1)61Gpb/1 J mice (R6/1). Those models mimic neuronal damage and systemic manifestations of HD. The objective of this work was to study the participation of TLR4 in the manifestations of neuronal damage and HD symptoms in the two mentioned models. For this purpose, C57BL6/J and TLR4-KO mice were administered with QA, and after that motor activity, and neuronal and oxidative damages were measured. R6/1 and TLR4-KO were mated to study the effect of low expression of TLR4 on the phenotype manifestation in R6/1 mice. We found that TLR4 is involved in motor activity, and neurological and oxidative damage induced by intrastriatal injection of QA, and the low expression of TLR4 causes a delay in the onset of phenotypic manifestations by the mHtt expression in R6/1 mice. Our results show that TLR4 is involved in both models of HD and focuses then as a therapeutic target for some deleterious reactions in HD.
Toll样受体(TLRs)是先天免疫反应的核心参与者。它们在神经胶质细胞和神经元中表达,其过度激活会导致促炎分子的产生、神经炎症以及与许多神经退行性疾病(如亨廷顿舞蹈病,HD)相关的神经损伤。HD是一种由编码亨廷顿蛋白(Htt)的基因突变引起的遗传性疾病。突变型Htt(mHtt)的表达会导致进行性神经元变性,其特征为纹状体中γ-氨基丁酸能神经元丧失、氧化损伤、神经炎症过程以及运动行为受损。研究HD的主要动物模型是纹状体内注射喹啉酸(QA)以及转基因B6CBA-Tg (HDexon1)61Gpb/1 J小鼠(R6/1)。这些模型模拟了HD的神经元损伤和全身表现。本研究的目的是探讨TLR4在上述两种模型中神经元损伤表现和HD症状中的作用。为此,给C57BL6/J和TLR4基因敲除(KO)小鼠注射QA,之后测量其运动活性、神经元损伤和氧化损伤。将R6/1小鼠与TLR4-KO小鼠交配,以研究TLR4低表达对R6/1小鼠表型表现的影响。我们发现,TLR4参与了纹状体内注射QA所诱导的运动活性、神经损伤和氧化损伤,并且TLR4低表达会导致R6/1小鼠中mHtt表达引起的表型表现发作延迟。我们的结果表明,TLR4参与了HD的两种模型,因此可作为HD中某些有害反应的治疗靶点。